Exco InTouch announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology guidelines for Health Insurance Portability and Accountability Act security.
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology (NIST) guidelines for Health Insurance Portability and Accountability Act (HIPAA) security.
HIPAA rules constitute a set of regulations from the US Department of Health & Human Services relating to any Protected Health Information (PHI) that identifies health or financial data of US citizens stored on computer systems. The Security Rule specifies a series of administrative, physical, and technical safeguards for covered entities and their business associates to use to assure the confidentiality, integrity, and availability of electronic PHI.
Dale Jessop, Chief Technology Officer at Exco InTouch commented “Security of data and the protection of personal information remain the highest priority for Exco InTouch. Whilst no formal certification for HIPAA exists, to be independently audited against NIST guidelines for HIPAA security provides further reassurance to our customers that Exco InTouch business operations are aligned to comply with HIPAA standards.”
Tim Davis, CEO and co-founder of Exco InTouch added “I am extremely proud of the team involved throughout the audit process, and also that of the 64 HIPAA citations we were audited on, no findings were reported". As a result of this audit, Exco InTouch customers (for whom the company provides mobile and digital patient engagement solutions), can continue to be assured that their programs comply with these stringent security safeguards.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.